As of 2019, alpelisib is FDA approved for the treatment of metastatic PIK3CA-mutant, HR+ breast cancers in combination with the estrogen receptor (ER) antagonist fulvestrant (2). The gene discussed is ESR1; the disease is breast carcinoma.